Olverembatinib granted breakthrough therapy designation for the treatment of philadelphia chromosome-positive (ph+) acute lymphoblastic leukemia (all)

Rockville, md. and suzhou, china, march 05, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a breakthrough therapy designation (btd) by the center for drug evaluation (cde) of china's national medical products administration (nmpa), for combination with low-intensity chemotherapy for the first-line treatment of newly-diagnosed patients with philadelphia chromosome-positive (ph+) acute lymphoblastic leukemia (all).
AAPG Ratings Summary
AAPG Quant Ranking